Clinical Trial Update: Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nivolumab and ipilimumab with or without cabozantinib for recurrent or metastatic nasopharyngeal carcinoma is currently recruiting. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Cabometyx (cabozantinib)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma | Phase 2 | Status: RECRUITING